Podcasts about controlled substance act

Episode 181: Cannabinoid Hyperemesis SyndromeFuture Dr. Johnson explains the pathophysiology, assessment, and management of Cannabinoid Hyperemesis syndrome. Dr. Arreaza adds some insights on the topic.  Written by Tyler Johnson, MSIV, Western University of Health Sciences, College of Osteopathic Medicine of the Pacific-Northwest. Editing and comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Definition Cannabinoid hyperemesis syndrome (CHS) is a syndrome of cyclic abdominal pain, vomiting, or nausea in older adolescents and adults who have chronic ϲаnոаbis use.The term “marijuana” is considered racist by some people. In the 1930s, American politicians popularized the term “marijuana” in the U.S. to portray the drug as a “Mexican vice” and to have a justification to persecute Mexican immigrants. Epidemiology The overall prevalence of cannabinoid hyperemesis syndrome is unknown due to a lack of definitive criteria or diagnostic tests. It occurs in a population that may not disclose substance use. One study conducted in 2015 in a United States urban emergency department not named, found one-third of patients with near-daily cannabis use met criteria for having had CНЅ in the prior six months.Why are rates of CHS increasing?Between 2005-2014 hospitalizations cyclic vomiting syndromes increased by 60 %. concurrent cannabis use in hospitalized patients increasing from 2 to 21 percent. 7 years after the commercialization of cannabis in Canada, the Canadian health services found a 13-fold increase in cyclic vomiting syndromesPotential correlations for the increase in CHS are increased legalization and commercialization of cannabis, higher tetrahydrocannabinol concentrations in cannabis products, and increased recognition of the syndrome.Legal status of Cannabis in the USCannabis is legal in 24 states: Alaska, Arizona, California, Colorado, Connecticut, Delaware, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nevada, New Jersey, New Mexico, New York, Ohio, Oregon, Rhode Island, Vermont, Virginia, and Washington. It is also legal in Washington, D.C. Cannabis is approved for medical use in 38 states.Federal level: Cannabis is a Schedule I drug, under the Controlled Substance Act (added in 1970) in the group of Hallucinogenic or psychedelic substances. Tetra-hydro-cannabinol (THC, a “mind-altering substance in cannabis”) is on the same list. However, cannabidiol (CBD, derived from hemp or non-hemp plants) was removed from the Controlled Substances Act in 2018. CBD is FDA-approved (under the name of Epidiolex®) to treat rare seizure disorders. CBD is still on the list of controlled substances in some states. I see THC as a problem.THC increased concentration As recreational Cannabis becomes more normalized, innovators look to find new ways to differentiate their product and increasing THC has become a common way to perform this similar to alcohol content in the beer, wine, and liquor industry. An article by Yale School of Medicine titled “Marijuana: Rising THC Concentrations in Cannabis Can Pose Health Risks” states, “In 1995, the average THC content in cannabis seized by the Drug Enforcement Administration was about 4%. By 2017, it had risen to 17% and continues to increase. Beyond the plant, a staggering array of other cannabis products with an even higher THC content like dabs, oils, and edibles are readily available—some as high as 90%.”Recently, cannabis-infused water started to be sold in some grocery stores.Pathophysiology of CHSIt is not entirely understood. Some suggest multifactorial involving cannabinoid metabolism, exposure dose and tolerance modifying receptor regulation, complex pharmacodynamics at Cannabinoid receptors, and even changes in genetics and cannabinoid variation in plants. CB1 receptors are involved in gastric secretion, sensation, motility, inflammation, and lipogenesis. The activation of CB1 and CB2 receptors has been suggested as the possible cause of CHS.Risk FactorsCHS can occur after acute or acute on chronic use but many report daily 3-5x cannabis use cannabis use over one year and many over at least two years. Median age 24 years. Interesting factsMedical visits for inhaled cannabis are more likely associated with CHS while edibles are more likely for acute psychiatric reactions.Also, CHS is a paradoxical effect since cannabis and cannabinoid receptor agonists are known antiemetics (as seen in nabilone and dronabinol (synthetic analogs of THC)) and prescribed by some physicians to combat chemotherapy effects.Clinical Features of CHSCyclical pattern with abdominal pain, severe nausea, and vomiting up to 30 episodes daily. Pain is intense and even referred to as “scromiting” due to its intense nature, causing patients to scream and vomit concurrently.Typically, it presents with 2 or more episodes over a 6-month period with no symptoms in between. It starts within 24 hours of last cannabis use (differentiating from cannabis withdrawal) and occurs at day or night. There is a gradual symptom resolution of nausea and vomiting after several days of cannabis cessation. Some patients had symptoms 2 days to 2 weeks after cessation. Diagnosis of CHSClinical diagnosisRule out neurological symptoms such as migraine headaches, acute abdomen, motion sickness, and medications, such as recent antibiotics and chemotherapy.Often the diagnosis is discovered with a thorough history reporting a decrease in symptoms with hot showers/baths.Management of CHS AcuteRehydrate with Fluids Dopamine Antagonists– Droperidol (0.625 or 1.25mg) /Haloperidol (0.05 to 0.1mg/kg with max dose of 5mg initially) favored over typical antiemetics like Zofran or Reglan.If needed, combine with an antiemetic like metoclopramide IM or ondansetron IV and consider patients' dehydration status likely requiring US-guided IV.Topical capsaicin cream 0.025 – 0.1% on the abdomen. Long term97% resolution of symptoms completely in a systematic review of patients who stopped cannabis use.Reinforce it may take several weeks of abstinence for symptoms to resolve and symptoms can worsen if cannabis is resumed. It is unknown if a reduction in use can prevent recurrence.Approaches in the clinicEducate patients on the etiology of their symptoms with complete cessation of cannabis use.Consider referral to counseling for cannabis use disorder and abstinence support for treatment-seeking cannabis users. Approach topics such as changing one's environment, seeking social support, and using self-help techniques to non-treatment-seeking individuals.Consider referring patients with polysubstance use and significant comorbidities to a supervised withdrawal management setting. Conclusion: Cannabis use is increasing with legalization and commercialization across the United States. With increased use, Cannabinoid hyperemesis syndrome incidence increases. Often it can be diagnosed with a thorough history including chronic cannabis consumption and symptomatic relief by showers. Physicians will need to develop counseling approaches to better understand CHS patients and how to approach an often-difficult topic.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Angulo MI. Cannabinoid Hyperemesis Syndrome. JAMA. 2024;332(17):1496. doi:10.1001/jama.2024.9716. Link: https://jamanetwork.com/journals/jama/fullarticle/2824833#:~:text=Cannabinoid%20hyperemesis%20syndrome%20(CHS,last%20less%20than%201%20week.Backman, Isabella, Marijuana: Rising THC Concentrations in Cannabis Can Pose Health Risks, Yale School of Medicine, August 30, 2023. https://medicine.yale.edu/news-article/not-your-grandmothers-marijuana-rising-thc-concentrations-in-cannabis-can-pose-devastating-health-risks/Buchanan, Jennie A and George Sam Wang, Cannabinoid Hyperemesis Syndrome, Up To Date, updated July 17, 2024. https://www.uptodate.com/contents/cannabinoid-hyperemesis-syndromeTheme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

In this week's episode, Isaiah Buchanan and Mary O'Connell discuss the latest news in the trucking industry. They delve into a new Controlled Substance Act ruling that could have significant impacts on drivers, the current state of the freight market, and the ongoing recovery from recent natural disasters. Key Topics: New CSA ruling and its potential consequences Freight market outlook for Q4 and beyond Impact of natural disasters on the supply chain Tips for navigating the industry challenges Don't miss this informative discussion! Watch the full episode on our YouTube channel. #truckingnews #freight #CSA #supplychain #logistics

Psychedelic scholar, Robert Forte, returned to the podcast to FINALLY set the record straight on MDMA, MAPS and the FDA's recent (and salient) decision to not approve Rick Doblin's MDMA trauma therapy proposal, which the fake alt media community would have us believing is some sort of travesty. Oy.Part 2:danikatz.locals.comwww.patreon.com/danikatzwww.danikatz.comFind Robert:Twitter: @divinecomedy56https://www.alteredstatesofamerica.net/https://alteredstatesofamerica.substack.com/Show notes:Returning to the USA from GreeceSetting the record straight: MDMA, MAPS & the FDARFK & drug policy advisoryUpholding “The Narrative”: Joe Rogan, Aubrey Marcus, Jordan PetersonPsychedelic field researchersOrigins of Forte's MDMA journeyUS Neo-Conservatism & TotalitarianismTimothy Leary and Frank BaronConference of 1981 and Esalen InstituteHunter S. ThompsonDoblin- Secret snitch to Drug Guru and media darling“Conspiracy theorist” label vs real drug-related conspiraciesAmanda Fielding, Rebel Wisdom, ConspiritualityBooks: CIA, drug trade conspiraciesWWII: OSS members to Harvard professors/CIATimothy Leary: 1948 CIA funded MKUltraOperation Paperclip- Nazi's into USAAmerican Spirit diluted with drug psyops40's-50's psychedelic researchLeary- flawed character with anti-authoritarian spirit1985- Forte at U of Chicago- religion studyCharles Schuster & MDMA brain damageSchedule 1 drug & most popular drug in the worldEcstasy & Rave movement- drug deployment psychological warfareSalon article: art students, Mossad spies, DEA & drug ringsRick Doblin- questionable credentialsHeseg Foundation- “greatest moment of his life”Disclaimer- re Israel‘Orphan drug'- MDMA has no owner/no $ for PharmaAlex Shulgin- Bohemian GroveHuxley- Soma for the masses1984- MAPS (scam) launched- non-profit to $15kLeonard Pickard- DIA, LSD, & MDMAWhere is MAPS now?1970=Controlled Substance Act$16 million grant at Harvard for psychedelic researchBring MDMA back to consciousness explorationBill Maher and story-tellingAltered States of America and psychedelic movements

Episode 50 We interview Kara Cook about her study about the Controlled Substance Act and unintended harms. Kara's brother-in-law, Darren, tragically lost his life at 40 years old due to lack of access to opioids. Kara Cook is concurrently a lecturer in the Department of Statistics and a doctoral candidate in the PhD program in Epidemiology and Biostatistics in the College of Public Health.  Her research interests include advancing our understanding of public health issues, with a primary focus on substance use disorder and its intersection with public policy.  She is interested in using statistical methodologies to gather evidence about the effects of public policy, specifically scheduling, on many facets of substance use with a focus on the Appalachian region of Kentucky. The Doctor Patient Forum is a national nonprofit organization fighting for the rights of pain patients and their providers. We bring awareness to the untreated pain and patient abandonment crisis. We are also knows as Don't Punish Pain Rally. ⁠https://www.patreon.com/thedoctorpatientforum⁠ ⁠https://www.thedoctorpatientforum.com/⁠ The information in this podcast is not to be considered legal or medical advice.

This Legally Speaking episode examines one of the largest dark net drug trafficking cases in Utah. In 2019, Aaron Shamo was sentenced to life in prison under the Controlled Substance Act for running a massive Fentanyl and Xanax manufacturing and distribution scheme. A case of this magnitude is fascinating. In this interview, Assistant Attorney General Michael Gadd, who worked with the Department of Justice, shares more details about this case. Explore these resources to learn more: DOJ News Release on Shamo's Conviction Shamo accomplices convicted CNBC Documentary on Shamo case

Earlier this month, Oregon State University received $10 million from the U.S. Department of Agriculture to work with a coalition of Native American tribes to explore opportunities to manufacture products and materials made from hemp. Some of those industrial applications include turning it into carbon for use inside energy storage devices, processing hemp fiber for use in car door panels and floorboards and mixing the interior part of the stalk with lime and water to make a lightweight alternative to concrete in home construction. The federal ban on growing hemp ended in 2018 when Congress legalized its production as an agricultural commodity, and removed it as a Schedule I drug under the Controlled Substance Act.  OSU’s Global Hemp Innovation Center is collaborating with 13 tribal nations in Oregon, Washington, Montana and Idaho on this effort which will also include educational outreach and workforce training opportunities. Joining us to share details of this partnership are: Jeff Steiner, the director of the Global Hemp Innovation Center at OSU; Jim Souers, an enrolled member of the Cheyenne River Sioux Tribe and the CEO of the Warm Springs Economic Development Corporation; Mary Jane Oatman, an enrolled member of the Nez Perce Tribe, a descendant of the Delaware Tribe and the Executive Director and Chief Operating Officer of the Indigenous Cannabis Industry Association.  

Welcome home!  This week, hosts Angela Rye, Andrew Gillum, and Tiffany Cross start the show with a look at Trump's recent “bloodbath” debacle.  Trump's violent language on the campaign trail is nothing new, so how concerned should we be about political violence? What are the lasting effects of promoting violence as a political strategy? Is it “terrorism”??  Plus, you remember the First Step Act, that bipartisan criminal justice reform bill passed by the 115th Congress and signed into law by Donald Trump in 2018 that Republicans were patting themselves on the back for? You might have missed it in the mainstream news, but the ultra conservative Supreme Court just struck down a key part of the bill and the Justice who drafted the majority opinion MIGHT surprise you! The hosts dig into the SCOTUS ruling for this week's deep dive.  Are you HIGH? Or feeling low because Mary Jane is still a Schedule I substance under the Controlled Substance ACT? Well, MVP Harris has some thoughts on it. If you're in Baltimore, support Marilyn Mosby by showing up to her rally. It's at noon this Saturday March 23rd at the Druid Hill YMCA and this is just... the first step.  And since we know so many of you listen just for Tiffany's sports analysis, she'll be back to break down March Madness in this week's Politics Are Everywhere. You can fill out your NCAA Women's (and men's) March Madness Bracket on the NCAA website.  —--------- We want to hear from you! Send us a video @nativelandpod and we may feature you on the podcast.  Instagram  X/Twitter Facebook Watch full episodes of Native Land Pod here on Youtube. Thank you to the Native Land Pod team:  Angela Rye as host, executive producer and cofounder of Reasoned Choice Media; Tiffany Cross as host and producer, Andrew Gillum as host and producer, and Gabrielle Collins as executive producer; Loren Mychael is our research producer, and Nikolas Harter is our editor and producer. A special thanks as well to Chris Morrow and Lenard McKelvey, co-founders of Reasoned Choice Media.See omnystudio.com/listener for privacy information.

Today on Cannabis Talk 101, Connor & Daniel deliver some news you can use of all sorts including how Tensions arise between DEA Officials & Biden Administration over Rescheduling of Cannabis under Controlled Substance Act, Over 32,000 Studies have been published In Last Decade in regards to Cannabis Research, & Over 1 in 10 high school seniors report using delta-8 THC! Cannabis Talk 101, “The World's #1 Source For Everything Cannabis”, made global history by becoming the first cannabis show to partner with iHeartMedia, on 4/20/2020. Thank you for listening & watching Cannabis Talk 101 with Christopher Wright, aka "Blue" the CEO and creator of Cannabis Talk 101 and the Cannabis Talk Network. & Joe Grande, former Co-Host on Big Boy's Neighborhood on Power 106 FM, On-Air with Ryan Seacrest on 102.7 KIIS FM in Los Angeles and The Dog House in the Bay Area on WILD 94.9 KYLD. Toking with the Stars with Chuckie & Marty, & Financial Fridays with Tony Kassaei, The Inside Investor, on YouTube, IHeartRadio App, Spotify, & Apple Podcasts. Check out the Cannabis Talk Magazine (HERE).Call us anytime: 1-800-420-1980FOLLOW US on all Social Media: Linkedin: @CannabisTalk101Instagram: @CannabisTalk101 Tik Tok @CannabisTalk101: Facebook: / CannabisTalk101 Twitter: / CannabisTalk101 @BLUE @JoeGrande@Tony Kassaei The Insider Investor@CHUCKIE FUEGO@MARTY GRIMES See omnystudio.com/listener for privacy information.

Today on Cannabis Talk 101, Connor & Daniel deliver some news you can use of all types from MedMen™ closing all but two of it's Storefronts weeks after company's stock value plummets to zero, Cannabis Consumers Just as Likely to Exercise as Non-Consumers according to a new study, & DEA looking to reschedule it from Schedule 1 to Schedule 3 in regards to the Controlled Substance Act! Cannabis Talk 101, “The World's #1 Source For Everything Cannabis”, made global history by becoming the first cannabis show to partner with iHeartMedia, on 4/20/2020. Thank you for listening & watching Cannabis Talk 101 with Christopher Wright, aka "Blue" the CEO and creator of Cannabis Talk 101 and the Cannabis Talk Network. & Joe Grande, former Co-Host on Big Boy's Neighborhood on Power 106 FM, On-Air with Ryan Seacrest on 102.7 KIIS FM in Los Angeles and The Dog House in the Bay Area on WILD 94.9 KYLD. Toking with the Stars with Chuckie & Marty, & Financial Fridays with Tony Kassaei, The Inside Investor, on YouTube, IHeartRadio App, Spotify, & Apple Podcasts. Check out the Cannabis Talk Magazine (HERE).Call us anytime: 1-800-420-1980FOLLOW US on all Social Media: Linkedin: @CannabisTalk101Instagram: @CannabisTalk101 Tik Tok @CannabisTalk101: Facebook: / CannabisTalk101 Twitter: / CannabisTalk101 @BLUE @JoeGrande@Tony Kassaei The Insider Investor@CHUCKIE FUEGO@MARTY GRIMES See omnystudio.com/listener for privacy information.

The latest bill to federally legalize cannabis was reintroduced to Congress last week calling for the amendment of the Controlled Substance Act. This latest measure, known as the STATES Reform Act is one of several legislative attempts to ease federal restrictions on what is still currently a Schedule I substance. The bipartisan bill sponsored by Senator Nancy Mace was first introduced in 2021 under an equally oppositional house speaker. The New Marijuana Legalization Bill: What You Need To Know | Cannabis News We have yet to see what changes have been made as this version has not been made publicly available at this time. Senator Nancy Mace has been a long time advocate of federal legalization of cannabis. Even though several bills on the subject are under consideration, it remains to be seen which will prevail. It is clear though that the movement for legalization has grown significantly in the last few years and more states are being open to the idea. The STATES Reform Act would serve as a stepping stone towards this goal. The Act seeks to remove cannabis from the Controlled Substances Act (CSA) and allow states to regulate it in their own way. It also aims to create an environment that encourages businesses and individuals to operate legally and provides a pathway for those with convictions related to cannabis offenses. The STATES Act has been seen as a major step forward for the legalization movement, but there is still work to be done. As more states move towards legalizing cannabis, most federal bills such as these take the back burner while Congress seeks to address budget issues prior to another government shutdown. Tune in to hear about this story and the other top stories of the week on Cannabis Legalization News. Get in touch with us:

After a 6 month break Todd & Craig are back in the mother-ship. We want to thank all the listeners for their overwhelming support of the show. This episode will not disappoint and brings you the same Todd & Craig you have listened to for years. This episode covers marijuana as a schedule 1 substance under the Controlled Substance Act. Hold on tight don't let go sit back and enjoy the show.

In every other industry, there is a balance between the regulator and the regulated. This doesn't exist In this controlled substance space. “I think the cannabis movement is a failure… the whole cannabis movement is fractured — businesses are one page, criminal justice [reformers] on another page.” Matt Zorn This week we sit down with Matt Zorn to discuss the following:How to Fix the Cannabis Industry, 280ERescheduling of Controlled SubstancesHow he's pushing back on Government Red tape.Aligning State and Federal ReformAbout Matt Zorn:He has significant expertise in federal jurisdiction and procedure. Matt is at home digging out case-changing evidence, crafting legal strategies under arcane statutes and procedures, eliciting critical deposition or trial testimony, and arguing on his feet to trial courts, appellate courts, and arbitrators.Matt is also recognized as an authority on issues relating to the federal Controlled Substance Act and relating to cannabis regulation, even being named to the Law360 2020 Cannabis Editorial Advisory Board. Matt routinely speaks and publishes on issues relating to legal issues relating to controlled substances.Matt has received national recognition for his work in IP and controlled substances litigation. The American Lawyer recently named Matt a finalist for Young Lawyer of the Year (Litigation), and the American Inns of Court named him a 2020 Pegasus Scholar. Best Lawyers in America named Matt “One to Watch,” and Thomson Reuters' Super Lawyers recognized him as a “Texas Rising Star” in IP Litigation, Cannabis Law, and Administrative Law.Before joining the firm, Matt was a judicial clerk to the Hon. Rodney Gilstrap, U.S. District Judge for the Eastern District of Texas, spending hundreds of hours in court helping manage one of the busiest trial dockets in the country. Before then he was a litigator with Paul, Weiss in New York City. Guest Links:https://www.yettercoleman.com/https://ondrugs.substack.com/Follow us: Our Links.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here:

In every other industry, there is a balance between the regulator and the regulated. This doesn't exist In this controlled substance space. “I think the cannabis movement is a failure… the whole cannabis movement is fractured — businesses are one page, criminal justice [reformers] on another page.” Matt Zorn This week we sit down with Matt Zorn to discuss the following:How to Fix the Cannabis Industry, 280ERescheduling of Controlled SubstancesHow he's pushing back on Government Red tape.Aligning State and Federal ReformAbout Matt Zorn:He has significant expertise in federal jurisdiction and procedure. Matt is at home digging out case-changing evidence, crafting legal strategies under arcane statutes and procedures, eliciting critical deposition or trial testimony, and arguing on his feet to trial courts, appellate courts, and arbitrators.Matt is also recognized as an authority on issues relating to the federal Controlled Substance Act and relating to cannabis regulation, even being named to the Law360 2020 Cannabis Editorial Advisory Board. Matt routinely speaks and publishes on issues relating to legal issues relating to controlled substances.Matt has received national recognition for his work in IP and controlled substances litigation. The American Lawyer recently named Matt a finalist for Young Lawyer of the Year (Litigation), and the American Inns of Court named him a 2020 Pegasus Scholar. Best Lawyers in America named Matt “One to Watch,” and Thomson Reuters' Super Lawyers recognized him as a “Texas Rising Star” in IP Litigation, Cannabis Law, and Administrative Law.Before joining the firm, Matt was a judicial clerk to the Hon. Rodney Gilstrap, U.S. District Judge for the Eastern District of Texas, spending hundreds of hours in court helping manage one of the busiest trial dockets in the country. Before then he was a litigator with Paul, Weiss in New York City. Guest Links:https://www.yettercoleman.com/https://ondrugs.substack.com/Follow us: Our Links.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here:

In every other industry, there is a balance between the regulator and the regulated. This doesn't exist In this controlled substance space. “I think the cannabis movement is a failure… the whole cannabis movement is fractured — businesses are one page, criminal justice [reformers] on another page.” Matt Zorn This week we sit down with Matt Zorn to discuss the following:How to Fix the Cannabis Industry, 280ERescheduling of Controlled SubstancesHow he's pushing back on Government Red tape.Aligning State and Federal ReformAbout Matt Zorn:He has significant expertise in federal jurisdiction and procedure. Matt is at home digging out case-changing evidence, crafting legal strategies under arcane statutes and procedures, eliciting critical deposition or trial testimony, and arguing on his feet to trial courts, appellate courts, and arbitrators.Matt is also recognized as an authority on issues relating to the federal Controlled Substance Act and relating to cannabis regulation, even being named to the Law360 2020 Cannabis Editorial Advisory Board. Matt routinely speaks and publishes on issues relating to legal issues relating to controlled substances.Matt has received national recognition for his work in IP and controlled substances litigation. The American Lawyer recently named Matt a finalist for Young Lawyer of the Year (Litigation), and the American Inns of Court named him a 2020 Pegasus Scholar. Best Lawyers in America named Matt “One to Watch,” and Thomson Reuters' Super Lawyers recognized him as a “Texas Rising Star” in IP Litigation, Cannabis Law, and Administrative Law.Before joining the firm, Matt was a judicial clerk to the Hon. Rodney Gilstrap, U.S. District Judge for the Eastern District of Texas, spending hundreds of hours in court helping manage one of the busiest trial dockets in the country. Before then he was a litigator with Paul, Weiss in New York City. Guest Links:https://www.yettercoleman.com/https://ondrugs.substack.com/Follow us: Our Links.At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain The Dime is a top 5% most shared  global podcast The Dime is a top 50 Cannabis Podcast Sign up for our playbook here:

In about the last 10 years, the legalized cannabis industry has grown into a $32 billion business. Today, in 21 states, and the District of Columbia, you can legally purchase recreational marijuana if you are 21 or older. And 37 states have legalized medical marijuana programs. While it's easy to feel that cannabis has come a long way from the scare tactics of Reefer Madness, since 1970's Controlled Substance Act, marijuana has been classified as a drug on par with cocaine and heroin - dramatically increasing penalties for possession, sale, and distribution. Those penalties were enforced in ways that continue to disproportionately target people of color, especially black people. While the same states that once prosecuted the sale of weed are now regulating and taxing it, will those most affected by the punitive frameworks of the past be able to profit too? Host Michel Martin speaks with Devin Alexander, owner of the cannabis delivery business, Rolling Releaf, based in Newton Massachusetts. And we hear from Tauhid Chappell, President of the Philadelphia CannaBusiness Association.

The 30-Day Metabolism Makeover Course- if you are ready to reset your hormones, reduce inflammation, rebalance your mood and get yourself into the best shape of your life. If so, let's get your body into weight loss mode by clicking on the link below: https://atlantaweightlossdoctor.com/makeover/ Now enjoy today's show!  On this week's episode of Reset, Renew, Revive, we're joined by psychedelic medicine expert Matt Zemon, CEO and founder of HAPPŸŸ, a mental health company that provides guided ketamine therapy and digital wellness programs. His new book is called Psychedelics for Everyone. Psychedelics are generally considered heart and mind expanders and they include everything from LSD, psilocybin mushrooms, ayahuasca, ketamine, DMT, and MDMA. Ketamine is the only psychedelic that's legal in the U.S. but many people travel to other countries to try other types. Using psychedelics can be therapeutic and healing, and it's a whole new area of medicine. Psychedelics can ease depression, anxiety, PTSD, OCD, eating disorders and even curb alcohol and nicotine use. They can help someone look at trauma without the judgment and shame usually associated with it. Many studies show them to be more effective than antidepressants after only one or two uses.  Even if you don't feel a psychedelic experience is right for you, it might be very healing for someone you know, as it helps with emotional challenges and behavioral modification.    KEY TAKEAWAYS [7:48] Why the Controlled Substance Act was passed [9:11] Psychedelics and neural pathways [13:26] Psychedelics and healing trauma [23:02] Options for psychedelics if you're willing to travel [26:49] What microdosing is and how it can help you [28:33] Protocols for micro-dosing   HOW TO CONNECT WITH OUR GUEST https://www.happyy.me/ https://www.mattzemon.com/resetrenewrevive https://www.instagram.com/matt.zemon/ https://www.linkedin.com/in/mattzemon/ Matt Zemon's Book: Psychedelics for Everyone (everywhere books are sold)   MEMORABLE QUOTES “When you take a psychedelic, the first thing it's going to do is quiet down your default mode network. So it changes the way you're looking at the world and, and the way the senses are being processed.” “It's like you've been skiing down the same mountain on the same tracks all the time, and someone just threw a fresh coat of powder and you can ski anywhere you want on the mountain.” “As we get older, we get into these ruts of thinking. Literally in our brain, the neurons are firing in the same directions all the time.”   Visit our store below: https://reviveatlmd.mindsharecommerce.com/ Code: First10 for 10% off Rejuvenate your Metabolism and Weight Loss Bundle Weight Loss Support Packets   Adrenal Complex™ 120 capsules Metal-x-Synergy 90 Vegetarian capsules These packets are designed to assist the body in using fat for fuel and to help support healthy insulin, cortisol, and energy metabolism. They provide great support for any weight loss program. This Bundle is great for everyone who needs to jump-start their metabolism, reset their gut microbiome as well as curb sugar, carb craving to start seeing the results you want on the scale!  

Biden is urging Governors to follow his lead on a state level, and called on the Attorney General and the Secretary of Health and Human Services to “review expeditiously” marijuana's classification under the federal Controlled Substance Act.  The Takeaway was joined by Maritza Perez, the Director of the Office of Federal Affairs at the Drug Policy Alliance to discuss Biden's pardon.  

Biden is urging Governors to follow his lead on a state level, and called on the Attorney General and the Secretary of Health and Human Services to “review expeditiously” marijuana's classification under the federal Controlled Substance Act.  The Takeaway was joined by Maritza Perez, the Director of the Office of Federal Affairs at the Drug Policy Alliance to discuss Biden's pardon.  

On this episode of Let's Be Blunt, Montel talks with Matt Zorn, Esq, a partner at Yetter Coleman, LLP. Matt is recognized as an authority on issues relating to the federal Controlled Substance Act and issues relating to canna regulation, even being named to the Law360 2020 Cannabis Editorial Advisory Board. Matt routinely speaks and publishes on issues relating to legal issues involving controlled substances. He was honored as a 2020 Pegasus Scholar by American Inns of Court. In one of his favorite areas of complex litigation, Best Lawyers in America named Matt "One to Watch," and Thomson Reuters' Super Lawyers recognized him as a "Texas Rising Star" in IP Litigation, Canna Law, and Administrative Law. Before joining the firm, Matt was a judicial clerk to the Hon. Rodney Gilstrap, U.S. District Judge for the Eastern District of Texas, spending hundreds of hours in court helping manage one of the busiest trial dockets in the country. Before then he was a litigator with Paul, Weiss in New York City. He earned his law degree at Columbia Law School, and his BA in European History and Applied Mathematics from Emory University.Support the show

Welcome to the third and final episode in our series on the potential of psilocybin-assisted therapy to relieve the existential distress of, and help us live as well as possible with, metastatic breast cancer. In this episode, we speak with two women taking action to increase legal access to psilocybin-assisted therapy in the United States. The first is a patient living with MBC who, along with her doctor, has brought a lawsuit against the Drug Enforcement Agency which is denying her access to psilocybin in the palliative care setting and under existing Right to Try laws for promising investigational medications for the terminally ill. The patient petitioner, Erinn Baldeschwiler, tells us why she joined the lawsuit, what she hopes to gain from psilocybin-assisted therapy, and what it's been like to deal with all the legal proceedings on top of a progressing MBC diagnosis. Our second interview in this episode is with the attorney who is leading the legal case to open access to psilocybin under Right to Try legislation, Kathryn Tucker of the Emerge Law Group. Kathryn explains why psilocybin should be immediately available to patients suffering from distress, anxiety, and depression under FDA rules and state and federal Right to Try laws. But the DEA is continuing to block access and hold psilocybin on Schedule 1 of the Controlled Substance Act. It's confusing, but we explain it all here. Lastly, see the episode notes for a current petition to the DEA to step out of the way and grant access to psilocybin to anyone with a terminal illness. This series has been led by our incredible series producer, Dr. Paula Jayne with expert assistance from co-host Lynda Weatherby (new to the podcast this season!), and senior producer and host Lisa Laudico. Thanks for listening!More info is available in our episode notes for this series on our website:  www.ourmbclife.org Got something to share? Feedback?Email:ourmbclife@sharecancersupport.org Send us a voice recording via email or through speakpipe on our website.  Follow us on Facebook, Instagram, and Twitter @ourmbclife  

Getting to the Heart of Cannabis Health Risks Cell Press Cannabis has deleterious effects on cardiovascular physiology. Wei et al. (Cell 185, May 12, 2022) confirm that important inflammatory markers increase transiently after a single marijuana joint and prove a mechanistic link between THC induced vascular inflammation, endothelial dysfunction, cellular oxidative stress, and atherosclerosis using cell-based and mouse models of atherosclerosis. They provide a pharmacological model in which THC-mediated activation of CB1 receptor signaling pathways converge on MAP kinase, TNFa, and NF-kB outputs to create a proinflammatory and atherogenic environment in endothelial cells.   That genistein can antagonize the negative effects of THC with minimal central effects is exciting because genistein is a common component of soy and is already a widely consumed dietary product.   Electronic Cigarettes Versus Nicotine Patches for Smoking Cessation in Pregnancy: A Randomized Controlled Trial Nature Medicine Pregnant smokers were randomized to use either nicotine replacement therapy with patches (NRT, n=571) or e-cigarettes (n=569) for smoking cessation. For the primary outcome, validated prolonged quit rates at the end of pregnancy, the results were 4.4% for NRT and 6.8% for e-cigarettes (P=0.08). However, 25 participants in the NRT arm who reported abstinence also used e-cigarettes. When these participants were excluded from data analysis the quit rates were 3.6% for NRT and 6.8% for e-cigarettes (P=0.02). Low birthweight was less common in the e-cigarette arm, 9.6% versus 14.8% for NRT (P=0.01). The authors conclude that “e-cigarettes were markedly more effective than patches” and do not pose more risk.   Daily Cannabis Use, Cannabis Use Disorder, and Any Medical Cannabis Use Among US Adults: Associations Within Racial, Ethnic, and Sexual Minoritized Identities in a Changing Policy Context Preventive Medicine Reports Cannabis use has steadily increased in the United States, with daily and medical use associated with cannabis use disorder (CUD) and the negative consequences more frequent among marginalized groups. In this study, the authors use the National Survey on Drug Use and Health (NSDUH) to examine medical and daily use and CUD across the intersections of racial, ethnic, and sexual minorities. They found that sexual minorities were more likely to have medical and daily use and CUD than their heterosexual counterparts within each racial and ethnic group. However, when examining the intersection of race, ethnicity and sexual identity, there was more heterogeneity across these groups. In addition, they found that in states with medical cannabis laws (MCL) daily cannabis use was higher across all intersectional groups.     Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial AJP Psychiatry Altered glutamatergic neurotransmission is implicated in the pathogenesis of major depressive disorder. AXS-05 (dextromethorphan-bupropion) is an oral NMDA receptor antagonist and sigma-1 receptor agonist, which utilizes inhibition of CYP2D6 to increase its bioavailability. This phase 2 trial assessed the efficacy and safety of dextromethorphan-bupropion in the treatment of major depressive disorder. In patients with major depression, dextromethorphan-bupropion (AXS-05) significantly improved depressive symptoms compared with bupropion and was generally well tolerated.  The most common adverse events were dizziness, nausea, dry mouth, decreased appetite, and anxiety. Dextromethorphan-bupropion was not associated with psychotomimetic effects, weight gain, or sexual dysfunction.   Mental Health and Substance Use Among Homeless Adolescents in the US JAMA Network This study evaluated mental health and substance use outcomes among homeless and non-homeless adolescents in 2019. Alcohol, cigarette, marijuana, and binge drinking during the prior 30 days was assessed, along with lifetime use of cocaine, methamphetamine, heroin, ecstasy, and injection drugs or prescription opioid misuse. Results found current substance use ranging from cigarettes to alcohol were higher among homeless adolescents. Lifetime cocaine use was significantly higher among homeless adolescents, as were methamphetamine, heroin, ecstasy, and injection drug use. Homeless adolescents experience worse mental health outcomes, including depression and suicidality, and struggle with more SUDs than their counterparts.   The Importance of Federal Action Supporting Overdose-Prevention Centers NEJM In this prospective piece, the authors discuss the need for new approaches to harm reduction and substance use disorder treatment in the face of substantially increasing overdose deaths, particularly since the start of the COVID-19 pandemic. One such strategy they discuss is overdose-prevention centers, which operate in other countries and are associated with significant reductions in opioid-overdose morbidity and mortality. However, under Section 856 of the Controlled Substances Act, such facilities may be subject to federal legal sanctions. The authors recommend that the Biden administration declare they will not interfere with such public health interventions or declare that section 856 does not apply to legally sanctioned centers. Further, Congress should modify the Controlled Substance Act to exempt overdose-prevention centers.    Complex Persistent Benzodiazepine Dependence—When Benzodiazepine Deprescribing Goes Awry JAMA Psychiatry Benzodiazepines remain popular medications among patients due to rapid symptom relief and reinforcing effects. As clinicians and patients become more aware of potential risks, and clinical guidelines increasingly urge caution in prescribing, guidance for benzodiazepine deprescribing is needed. The authors propose a new clinical concept for patients experiencing significant psychological or functional decline during or after a benzodiazepine taper—complex persistent benzodiazepine dependence (CPBD). CPBD can be described as symptomatic or functional decompensation with or without the development of aberrant medication behaviors in the setting of benzodiazepine deprescribing–in the absence of a benzodiazepine use disorder. Further research is needed to validate this concept.    What is Success in Treatment for Opioid Use Disorder? Perspectives of Physicians and Patients in Primary Care Settings JSAT Opioid abstinence and treatment retention are typically used as measures of success of MOUD treatment. This study sought to identify other important treatment outcomes and patient-centered measures of success. Qualitative, structured interviews were conducted with physicians (n=14)  and patients (n=18) in 2 family medicine residency programs. The physicians (7 faculty and 7 residents) were experienced buprenorphine prescribers. Both patients and physicians identified 5 themes: staying sober, and improvement in physical health, mental health, relationships, and role functioning. Patients, but not physicians, identified 2 additional themes: tapering off buprenorphine, and decreased stigma and shame. The authors conclude that “clinicians and researchers need to consider a broader scope of success indicators.”  

 Millions of Americans wait until the last minute to file their taxes and this year is no exception.Monday is Tax Day — the federal deadline for individual tax filing and payments — and the IRS will receive tens of millions of last-minute filings electronically and through paper forms.As of April 8, the IRS had received more than 103 million returns for this tax season, and it had issued more than 63 million refunds worth more than $204 billion.For comparison, last year more than 169 million people completed an income tax return by the end of the year. That probably leaves nearly 40% of this year's taxpayers still unaccounted for, with many scrambling to submit their documents by Monday.Nina Tross at the National Society of Tax Professionals says if people haven't filed their taxes by now, “they're better off filing an extension.”READ MORE: https://www.wcnc.com/article/news/nation-world/tax-day-irs-extension/507-38af10ee-0df4-4d48-b83a-e907d876b913There are thousands of hemp-based products sold across the state, but it could soon all become illegal.Hemp products have been legal in the state since 2015 when lawmakers passed the Hemp Pilot Program bill. It removed the term hemp from the definition of marijuana under the state's Controlled Substance Act. However, in January, the state's hemp farming laws expired. The state's hemp exemption laws will also expire by June 30. State lawmakers are considering a medical marijuana bill but its narrow definition would not include hemp. READ MORE: https://www.wcnc.com/article/news/local/hemp-based-products-could-become-illegal-in-north-carolina/83-e0602a87-1369-43ef-8d6d-52d8254be25eWatch Wake Up Charlotte each weekday morning from 4:30 to 7 a.m. on WCNC Charlotte, and as always, join the conversation on social media using #WakeUpCLT! 

This week's episode is all about drugs and the mindset needed to distribute drugs illegally.  Ruan v. U.S. asks whether a doctor accused of violating the Controlled Substance Act should be judged by an objective standard (would every doctor think this was wrong), or a subjective standard (did this doctor think this was wrong).  Law starts at (05:00).

Thomas Jefferson wrote, “Hemp is the health, wealth and security of this country”. During World War II, the U.S. Department of Agriculture had a “hemp for victory” campaign to encourage farmers to grow the plant. Yet illogical fears about the dangers of marijuana led to the passage of laws such as the Marihuana Tax Act of 1937 and the Controlled Substance Act of 1970 that severely discouraged farmers from growing hemp. On this episode of Let's Be Blunt, Montel talks with Matthew Harmon, the author of “Marijuana Hater's Guide to Making a Billion Dollars From Hemp”. Matthew is a seasoned real estate executive with a sharp eye for viable commercial and retail business ventures. When California decriminalized cannabis, business opportunities increased as prospective tenants took advantage of its new status. Researching the new industry, he was shocked to learn that hemp was classified as a Schedule One controlled substance at that time, despite the fact that it contains minimal amounts of the psychotropic ingredient in cannabis and cannot be used to get high. He educated himself on industrial hemp's historical significance, its thousands of commercial uses, and the plant's potential to support or replace current diminishing resources, and concluded that hemp seemed a far more impactful and sustainable business investment than cannabis. That set him on a mission to expose why industrial hemp had been criminalized for decades, and to lift the illogical and arbitrary laws that left the United States with a $78 million hemp trade deficit. Learn more about your ad-choices at https://www.iheartpodcastnetwork.com

The P.L.A.N.T.S. for Lyfe Team focuses on the history of cannabis in America. Listeners will learn why cannabis became an illegal substance and why it continues to be illegal. You will immediately hear that greed and racism are at the heart of the prohibition of this medicinal plant. The pharmaceutical company is the largest lobbying entity in the US and works to continue to keep cannabis off the legal market. The truth of this difficult topic may cause some to feel uncomfortable as we hear about the reasons for the war on drugs, the Controlled Substance Act, the 13th Amendment and the profitable prison industrial complex. The pending legislation called the M.O.R.E Act is explained which proposes that cannabis should be taxed to support social equity programs, release of prisoners for non-violent cannabis charges and expungement of records. All medical schools and nursing schools should be taught about the endocannabinoid system and the medicinal benefits of cannabis. Politicians need to be educated as well as the general public. Voting, being educated and staying involved is a must to bring these important changes to the laws in this country.

Before 1970, promising research was being conducted on the potential therapeutic effects of a broad category of psychedelic drug compounds, including substances such as psilocybin, DMT (dimethyltryptamine), LSD (lysergic acid diethylamide) and MDMA (methylenedioxymethamphetamine) — and then the Controlled Substance Act was signed into law, which labeled those substances as drugs of abuse with no medical value. The severely limited research conducted thereafter continued to demonstrate the potential of these compounds to provide therapeutic value, particularly for notoriously difficult diseases such as depression, addiction, PTSD and others. In the past few years, the relatively unattended field of psychedelic therapeutics is seeing a revival of activity and excitement, spawning innovative approaches and creating valuable companies in the process. Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (Profile) is one of the exciting new companies to enter the public domain, bringing a diversified pipeline and de-risked strategy that should usher the company right into phase 2 clinical trials. A public company since its IPO in December of 2020, Tryp aims to become a leader in the healthcare and drug development industries alongside others, including COMPASS Pathways Plc (NASDAQ: CMPS), Field Trip Health Ltd. (OTCQX: FTRPF) (CSE: FTRP), Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED).

Before 1970, promising research was being conducted on the potential therapeutic effects of a broad category of psychedelic drug compounds, including substances such as psilocybin, DMT (dimethyltryptamine), LSD (lysergic acid diethylamide) and MDMA (methylenedioxymethamphetamine) — and then the Controlled Substance Act was signed into law, which labeled those substances as drugs of abuse with no medical value. The severely limited research conducted thereafter continued to demonstrate the potential of these compounds to provide therapeutic value, particularly for notoriously difficult diseases such as depression, addiction, PTSD and others. In the past few years, the relatively unattended field of psychedelic therapeutics is seeing a revival of activity and excitement, spawning innovative approaches and creating valuable companies in the process. Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (Profile) is one of the exciting new companies to enter the public domain, bringing a diversified pipeline and de-risked strategy that should usher the company right into phase 2 clinical trials. A public company since its IPO in December of 2020, Tryp aims to become a leader in the healthcare and drug development industries alongside others, including COMPASS Pathways Plc (NASDAQ: CMPS), Field Trip Health Ltd. (OTCQX: FTRPF) (CSE: FTRP), Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF), Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED).

This episode kicks off Season 3 of the show, better known as ‘I Plead The Spliff.’ Tune in as we get into the nitty gritty of the legalities around cannabinoid therapy and medicine this season. Episode 1 dives into the Controlled Substance Act of 1970 aka the CSA! As always - shoot us a DM on FB or IG to continue the conversation, comment, subscribe and share this episode with a friend ✅

In this episode I will be talking to Paul Kratsas about his story that starts in 1990 when a drug deal went bad. Paul's last drug deal ended in him being shot in the face, robbed, car jacked, and being arrested in the hospital as the perpetrator of a crime. * Paul was sentenced to life with out the possibility of parole for one count of conspiracy to sell 5 kilos of cocaine even though there were never any drugs present at the scene of the instant offense, or anywhere else for that matter. * Paul refused to take a plea deal and went to trial and and lost. He was punished with a life sentence that the judge didn't want to give him, but his hands were tied. In 1994 when the crime bill was passed it doubled the mandatory minimums for drug offenders and took the judges discretion away from them in sentencing. * On February 5, 2021 Paul received a compassionate release from federal prison due to the first step act that was a bipartisan criminal justice bill that was signed into law by President Trump in December of 2018. Below is the section of the law that pertained to Paul. * Title IV makes a variety of sentencing reforms. Section 401 amends the Controlled Substance Act (21 U.S.C. § 801 et seq.) to constrain the application of sentencing enhancements for defendants with prior drug felony convictions by redefining “serious drug felony” and “serious violent felony,” to reduce the mandatory minimum sentence for a second violation from 20 years to 15 years, and to reduce the mandatory minimum sentence for a third violation from life to 25 years. It makes similar revisions to the Controlled Substance Import and Export Act at 21 U.S.C. § 960(b). * * Please sign these petitions: * Petition for release:

In this episode I will be talking to Paul Kratsas about his story that starts in 1990 when a drug deal went bad. Paul's last drug deal ended in him being shot in the face, robbed, car jacked, and being arrested in the hospital as the perpetrator of a crime. * Paul was sentenced to life with out the possibility of parole for one count of conspiracy to sell 5 kilos of cocaine even though there were never any drugs present at the scene of the instant offense, or anywhere else for that matter. * Paul refused to take a plea deal and went to trial and and lost. He was punished with a life sentence that the judge didn't want to give him, but his hands were tied. In 1994 when the crime bill was passed it doubled the mandatory minimums for drug offenders and took the judges discretion away from them in sentencing. * On February 5, 2021 Paul received a compassionate release from federal prison due to the first step act that was a bipartisan criminal justice bill that was signed into law by President Trump in December of 2018. Below is the section of the law that pertained to Paul. * Title IV makes a variety of sentencing reforms. Section 401 amends the Controlled Substance Act (21 U.S.C. § 801 et seq.) to constrain the application of sentencing enhancements for defendants with prior drug felony convictions by redefining “serious drug felony” and “serious violent felony,” to reduce the mandatory minimum sentence for a second violation from 20 years to 15 years, and to reduce the mandatory minimum sentence for a third violation from life to 25 years. It makes similar revisions to the Controlled Substance Import and Export Act at 21 U.S.C. § 960(b). * * Please sign these petitions: * Petition for release: Harold Morris (Junior) has been convicted and sentenced to 40 years in Maryland state prison for selling marijuana. https://www.change.org/p/larry-hogan-state-clemency-40-year-sentence-mandatory-minimum-20-years-for-marijuana-charges?recruiter=800793370&recruited_by_id=9a57b1b0-a612-11e7-bddc-7175760863b4&utm_source=share_petition&utm_medium=copylink&utm_campaign=petition_dashboard * Paul Kratsas Clemency Petition: https://www.change.org/p/u-s-senate-please-get-paul-g-kratsas-clemency-paperwork-to-trump?recruiter=727343240&utm_source=share_petition&utm_medium=facebook&utm_campaign=psf_combo_share_initial&utm_term=psf_combo_share_initial&recruited_by_id=7c6386d0-4707-11e7-ae3b-51c800175060&share_bandit_exp=initial-17725829-en-US&share_bandit_var=v0&utm_content=fht-17725829-en-us%3Av5&fbclid=IwAR09s1z4NodjzLMEfZ3oWExJZs8zgayha8dvM-7NbxnHXw4SH53NKVBGc20 * * Baltimore Sun News Article: https://www.baltimoresun.com/news/crime/bs-md-ci-cr-kratsas-compassionate-release-20210215-k3wisjaavzgn7gaeuuzea4wtju-story.html?fbclid=IwAR07e3n64_aBs08tlRm9vmd_FuA6e-NsCEI-nJ2lUvFsFeXvvuRMutEA6Qo * * You can follow Paul Kratsas here: * https://www.facebook.com/paul.kratsas.77 * * Live-Stream Locations: * https://www.facebook.com/nowheretogo.butupnow.9/videos/768660070719108 * https://www.youtube.com/watch?v=P2iyCAemN-k * * If you like the streaming platform that I am using called StreamYard use the link below to sign up with and receive a $10 credit for signing up. I will get a credit as well and that of course will help the show. * StreamYard Affiliate Link: https://streamyard.com?pal=5045291231739904 * * Here is where you can find Sean Dustin: * Linktree: * https://linktr.ee/Nowheretogobutup * To support the show through Patreon: * https://www.patreon.com/user?u=1985999 * You can also tip me through PayPal: * www.paypal.com * recipient: nowheretogobutupnow@gmail.com * The Cash App: * https://cash.app/ * Recipient: $nwtgbupod * Show Notes Writer: Sean Dustin * *

Valium is classified as a schedule four drug under the Controlled Substance Act.https://recoverypartnernetwork.com/drug/benzodiazepine/valium-addiction

Mike and Ritu are LIVE in this important episode. 5 years ago we started the discussion on the issue of the Controlled Substance Act of 1970 and how there were no provisions for EMS. The DEA came to the table to explain the conundrum we are in as an industry. There was only one option. CHANGE THE LAW! Well, guess what. That is exactly what was done. 3 years later, we finally have a draft version of the rules to comply with the law and Mike and Ritu break it down. This is an IMPORTANT episode that will affect every EMS Provider. Please share this widely to get the discussion going. Sit back, watch the video version on YouTube or Facebook and chill with us! Thanks for making the SecondShift the fastest growing podcast on the network! Please leave us a great review on iTunes or wherever you listen! We appreciate you so much.

I discuss the MORE ACT vote coming to a HOUSE vote on Sept 21, 2020. I touch on the Controlled Substance Act, decriminalization and reform of the War on Drugs. I also dive into giving criminals a second chance and how we can implement a set of laws that could help with giving non-violent offenders a second chance. I also make mention of someone I respect and hope to have on the show Attorney Ron Durbin! Take a Listen! Below is the link to the info I discussed and a link to our website so you can be a guest on our show! https://www.leafly.com/news/politics/marijuana-legalization-more-act-news https://www.2partypodcast.com/contact --- Support this podcast: https://podcasters.spotify.com/pod/show/twopartypodcast/support

Episode 3: Listen to get an update on the vaping illness, learn about why cannabis is illegal today, and hear our review of Gold 'n Grams' Grapefruit Live Resin and the Puffco Peak.

Huge episode filled with music, law, entertainment and more. Craig & Todd discuss the CSA of 1970 and the preemption clause. Under the doctrine of preemption, which is based on the Supremacy Clause, federal law preempts state law, even when laws conflict. Therefore, a federal court may require a state to stop certain behavior it believes interferes with, or is in conflict with, federal law. Within the CSA, congress intended to leave states room to enforce their own state drug laws.  Enjoy!!  

Let's talk about Marijuana with special guest Mary Pryor of www.cannaclusive.com. What is the 1970 Controlled Substance Act?  What does it mean for the people in prison for marijuana charges?  Is weed weaponized against black and brown people to justify imprisoning?  Where does the money come from within the Marijuana industry? How can you invest in the industry? 

Hemp is now legal with the signing of the Farm Bill. Most importantly it removes hemp and any hemp derivative from The Controlled Substance Act, putting its supervision under the USDA.  There are 50,000 plus uses of Hemp and its been since the beginning of time.  be sure to subscribe and tell a friend.  

In this segment with Stephen Siff, Associate Professor of Journalism at Miami University and the author of ‘Acid Hype: American News Media and the Psychedelic Experience,’ we get into the U.S. news media's role in the promotion, and in particular the "hype," of psychedelic drug use in the 1950s and '60s — initially by prominent public figures and the "Intelligentsia," and eventually the wider population more generally. We also get into the Nixon Administration's role in instigating the War on Drugs, and the role the US media played in propagandizing the government's agenda regarding the prohibition of psychedelic compounds and cannabis. The media has played a major role in the “branding” of psychedelics and cannabis, both in a positive and negative light (depending on the time, and the context of their legal status). As Stephen examines in his book and in this interview, the initial coverage of LSD and other psychedelic compounds was initially very positive, with media outlets “hyping” the use and potential applications of these substances, effectively branding the psychedelic experience as a countercultural phenomenon. Along with this, Stephen discusses the other role the U.S news media has played in our popular perceptions of these substances. Leading up to the eventual criminalization of these substances under the Controlled Substance Act in 1970, the news media shifted its coverage of these substances, playing into the Nixon and successive administrations’ propaganda campaign to demonize and stigmatize psychedelic and drug use more broadly. Stephen Siff, Ph.D. is an Associate Professor of Journalism and the author of ‘Acid Hype: American News Media and the Psychedelic Experience,’ an account of mainstream media’s introduction of new drugs and new styles of recreational drug use in the 1950s and 1960s. His research as a journalism historian examines news coverage and government propaganda about illegal drug use and drug users during the latter half of the twentieth century. He has also published research in Journalism History and Newspaper Research Journal. Learn more about and purchase ‘Acid Hype: American News Media and the Psychedelic Experience’ here: http://bit.ly/AcidHype This is a segment of episode #160 of Last Born In The Wilderness “Don't Believe The Hype: The Media, Branding Psychedelics, & The War On Drugs w/ Stephen Siff.” Listen to the full episode: http://bit.ly/LBWsiff DROP ME A LINE: (208) 918-2837 WEBSITE: https://www.lastborninthewilderness.com PATREON: http://bit.ly/LBWPATREON DONATE: Paypal: http://bit.ly/LBWPAYPAL Ko-Fi: http://bit.ly/LBWKOFI FOLLOW & LISTEN: SoundCloud: http://bit.ly/LBWSOUNDCLOUD iTunes: http://bit.ly/LBWITUNES Google Play: http://bit.ly/LBWGOOGLE Stitcher: http://bit.ly/LBWSTITCHER RadioPublic: http://bit.ly/LBWRADIOPUB YouTube: http://bit.ly/LBWYOUTUBE SOCIAL MEDIA: Facebook: http://bit.ly/LBWFACEBOOK Twitter: http://bit.ly/LBWTWITTER Instagram: http://bit.ly/LBWINSTA

In this episode, I speak with Stephen Siff, Associate Professor of Journalism at Miami University and the author of ‘Acid Hype: American News Media and the Psychedelic Experience.’ In this discussion, we get into the U.S. news media's role in the promotion, and in particular the "hype," of psychedelic drug use in the 1950s and '60s — initially by prominent public figures and the "Intelligentsia," and eventually the wider population more generally. We also get into the Nixon Administration's role in instigating the War on Drugs, and the role the US media played in propagandizing the government's agenda regarding the prohibition of psychedelic compounds and cannabis. As a proponent of cannabis and the psychedelic experience, I have become increasingly aware that our popular perception of psychedelic and cannabis use has largely been formed by very prominent cultural forces, in particular the U.S. news media, pro-capitalist interests, and the State. The media has played a major role in the “branding” of psychedelics and cannabis, both in a positive and negative light (depending on the time, and the context of their legal status). As Stephen examines in his book and in this interview, the initial coverage of LSD and other psychedelic compounds was initially very positive, with media outlets “hyping” the use and potential applications of these substances, effectively branding the psychedelic experience as a countercultural phenomenon. Along with this, Stephen discusses the other role the U.S news media has played in our popular perceptions of these substances. Leading up to the eventual criminalization of these substances under the Controlled Substance Act in 1970, the news media shifted its coverage of these substances, playing into the Nixon and successive administrations’ propaganda campaign to demonize and stigmatize psychedelic and drug use more broadly. Considering we are in the midst of a “psychedelic renaissance,” with a renewed interest in psychedelic research and cannabis legalization across the U.S. and the Western world, it is important to frame this subject within the broader historical context of the news media’s role in shaping the perceptions of these substances, in particular with something as valuable and important as the psychedelic experience. Stephen Siff, Ph.D. is an Associate Professor of Journalism and the author of ‘Acid Hype: American News Media and the Psychedelic Experience,’ an account of mainstream media’s introduction of new drugs and new styles of recreational drug use in the 1950s and 1960s. His research as a journalism historian examines news coverage and government propaganda about illegal drug use and drug users during the latter half of the twentieth century. He has also published research in Journalism History and Newspaper Research Journal.✦ ✦Source: http://bit.ly/SiffBio Episode Notes: - Learn more about and purchase Stephen’s book ‘Acid Hype: American News Media and the Psychedelic Experience’ here: http://bit.ly/AcidHype - Read Stephen’s article ‘The Illegalization of Marijuana: A Brief History’: http://bit.ly/2QHDi1X - The song featured in this episode is “Voodoo Doll” by Son of Dave from the album Shake A Bone. - DROP ME A LINE: (208) 918-2837 - WEBSITE: https://www.lastborninthewilderness.com - PATREON: http://bit.ly/LBWPATREON - DONATE: Paypal: http://bit.ly/LBWPAYPAL Ko-Fi: http://bit.ly/LBWKOFI - FOLLOW & LISTEN: SoundCloud: http://bit.ly/LBWSOUNDCLOUD iTunes: http://bit.ly/LBWITUNES Google Play: http://bit.ly/LBWGOOGLE Stitcher: http://bit.ly/LBWSTITCHER RadioPublic: http://bit.ly/LBWRADIOPUB YouTube: http://bit.ly/LBWYOUTUBE - SOCIAL MEDIA: Facebook: http://bit.ly/LBWFACEBOOK Twitter: http://bit.ly/LBWTWITTER Instagram: http://bit.ly/LBWINSTA

Do Psychedelics Help With Personal Development? In today's world, there is a resurgence around Psychedelic substances. Whether it's ayahuasca, shrooms, salvia divinorum, MDMA, or even cannabis, there is a renaissance around psychedelics and how they can aid mankind. Thought leaders like Joe Rogan, Dennis McKenna, Aubrey Marcus, and many more are stepping up to change how the human species deals with psychedelics at the civilization level. Do psychedelics really help with personal development? There is mounting evidence that this is the case. Psychedelics have been taboo for some time. Since the sweeping Controlled Substance Act of the 1970, psychedelics have been forced underground. Similar to ancient days when esoteric practices were demonized by the early Christian church, psychedelics have become hidden. Unfortunately, the personal development that can happen as a result of psychedelics has disappeared along with the substances themselves. Psychedelics are making a resurgence. In what would seem a dark moment for humanity, psychedelics have returned to the spotlight. On this episode of Beyond Homo Sapien, I chat with Paul Kaufman about this resurgence and how psychedelics can aid in personal development. Paul is involved in the legal cannabis industry in Oregon and he is an advocate for how psychedelics can be harnessed to assist in personal development. Paul is also an MMA fighter and BJJ practitioner with a deep understanding of personal development from a more generalized perspective. Let's dive into the show!

I discuss the topic of LSD and psychedelic substances: the origin of LSD, the Controlled Substance Act of 1970, LSD research, and LSD microdosing.    The Origin of American Compulsory Schooling The Inherent Nature of Compulsory Schooling Essay The Open School website YouTubeTwitterMindsBitchute PodbeanInstagram Edgar Cards' music and works of art: Bandcamp Instagram Twitter

Despite being legal in more than half the states of the US, cannabis, and hemp are still federally illegal and considered to have no medical benefit by the US government and listed as a Schedule 1 substance under the Controlled Substance Act. As it stands, farmers face several barriers to grow cannabis and hemp due to federal prohibition — including restricted access to banking, water rights, and crop insurance.   This history of hemp and cannabis is incredible and dates back to 1619 with our founding fathers.  In 1850, cannabis was added to US Pharmacopeia as a treatment for numerous afflictions, including tetanus, alcoholism, opiate addiction, anthrax, gout, convulsive disorders, excessive menstrual bleeding, among others.   In 1933 alcohol prohibition ends, and "cannabis concerns" arise at the US Federal level. In 1934, The Garrison Act passed, which outlawed cannabis among other drugs. In 1936, medical Marijuana is replaced by other pain relievers and is removed on the US Pharmacopeia in 1937. From the 1950s-1980s, cannabis is listed as a controlled substance and the US implements very strict mandatory minimum sentences for cannabis possession.  In 1996, California was the first state to legalize medical marijuana under prop 215. In 2014, Colorado was the first state to legalize adult use of cannabis. To date, more than 30 states have legalized cannabis. 

Today on Hempire our host Eileen Karpfinger is joined by 12-year-olds Alexis Bortell. She’s written a book, takes cannabis oil daily and is challenging the U.S. Controlled Substance Act by suing Attorney General Jeff Sessions. Approximately three years ago Alexis had to leave her home in Texas in order to treat her severe form of epilepsy — known as intractable epilepsy — with cannabis. Now she’s suing Sessions so that others like her won’t have to leave home in fear of retribution from the federal government if they, too, use medical marijuana. The suit aims to prove that the Controlled Substances Act, the statute governing federal drug policy, is unconstitutional as it relates to marijuana, according to Alexis’ attorney, Michael S. Hiller. Joining in on the suit with Alexis are plaintiffs Marvin Washington, a former NFL lineman; Jose Belen, an Army veteran; and Jagger Cotte, a 6-year-old Georgia boy with Leigh syndrome, all of whom use medicinal cannabis. The Cannabis Cultural Association is also named as a plaintiff, according to court documents.

Joe Mattia, founder of psychedelic resource and news site PsychedelicTimes.com, interviews M.A.P.S. (Multidisciplinary Association for Psychedelic Studies) founder Rick Doblin, on his experiences and his insights regarding the future of MDMA assisted psychotherapy. Rick shares some personal history, and references his own "coming out of the psychedelic closet." There's a mention of the Zendo, the harm reduction program set up by MAPS at festivals, a story about MAPS' beginnings at Esalen, and the use of Cannabis in the clinical trials.   Show Notes The history of psychedelics in the US: From William James’ experimentation with nitrous oxide in 1890 to the Controlled Substance Act in 1970 [3:58] The 1970s: Rick’s introduction to LSD, attendance of Stan Groff’s workshop at Esalen, and dropping out of school [8:00] The 1980s: Rick’s studies at Esalen, personal discovery of MDMA, and the start of MAPS as a psychedelic and medical marijuana pharmaceutical non-profit company [9:45] Why it’s important to work within the system [19:00] A possible alliance with the police, who experience high rates of PTSD and could benefit from this type of therapy [25:32] Current status of MDMA studies in Switzerland, Israel, Canada, and the US [29:16] Psilocybin research as end-of-life therapy [44:28] Phase 2 of MDMA research [46:46] Pros, cons, protocol, and challenges of using marijuana for PTSD [52:52] Phase 3 of MDMA research: How MAPS retains its nonprofit status by creating a Public Benefit Corp. [1:16:47] Phase 3 of MDMA research (cont): Therapist training program through MAPS and CIIS certification for psychedelic therapy [1:19:00] Zendo Project at Burning Man [1:30:43]  

Tom McClain is President of Hemp Logistics, and A Hemp Activist. His company markets and distributes hemp products. He is a big believer in Hemp, and supports the complete liberation of industrial hemp by having it removed from the schedule one list of the Controlled Substance Act. Tom was raised in rural Kansas and his family grew hemp until the 1930's. He graduated from Fort Hays State University in Hays, KS. He holds a bachelor of science degrees in Biology, Psychology and a Masters in Business Education from Tribhuvan University in Kathmandu, Nepal. Tom is very interested in helping local farmers have access to quality seed to grow Hemp and other agriculture crops in a sustainable organic way. He is helping to develop industrial production for Hemp and other natural fibers. Tom has worked in Jamaica, Costa Rica, Mexico, Thailand, India and Nepal. He has traveled extensively through Asia and Central America working in local economic development. Tom believes Hemp is an integral part of a sustainable economy for the US and developing nations and that hemp is the best suited crop for soil remediation here in the United States. Website: HempLogistics.com Email: tttMcClain@yahoo.com